KR102313314B1 - 신경퇴행성 질환 및 통증의 예방 및 치료에 사용하기 위한 화합물 - Google Patents

신경퇴행성 질환 및 통증의 예방 및 치료에 사용하기 위한 화합물 Download PDF

Info

Publication number
KR102313314B1
KR102313314B1 KR1020167013624A KR20167013624A KR102313314B1 KR 102313314 B1 KR102313314 B1 KR 102313314B1 KR 1020167013624 A KR1020167013624 A KR 1020167013624A KR 20167013624 A KR20167013624 A KR 20167013624A KR 102313314 B1 KR102313314 B1 KR 102313314B1
Authority
KR
South Korea
Prior art keywords
adenosine
pain
methyl
compound
bromothien
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167013624A
Other languages
English (en)
Korean (ko)
Other versions
KR20160086852A (ko
Inventor
짐민 팡
연리안 린
정신 린
천정 린
이주앙 천
나이귀 후앙
헝리 왕
벤자민 팡시엔 투
치청 첸
Original Assignee
아카데미아 시니카
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아카데미아 시니카 filed Critical 아카데미아 시니카
Publication of KR20160086852A publication Critical patent/KR20160086852A/ko
Application granted granted Critical
Publication of KR102313314B1 publication Critical patent/KR102313314B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
KR1020167013624A 2013-10-23 2014-10-22 신경퇴행성 질환 및 통증의 예방 및 치료에 사용하기 위한 화합물 Active KR102313314B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361894699P 2013-10-23 2013-10-23
US61/894,699 2013-10-23
PCT/US2014/061734 WO2015061426A1 (en) 2013-10-23 2014-10-22 Compounds for use in prevention and treatment of neurodegenerative diseases and pain

Publications (2)

Publication Number Publication Date
KR20160086852A KR20160086852A (ko) 2016-07-20
KR102313314B1 true KR102313314B1 (ko) 2021-10-19

Family

ID=52993493

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167013624A Active KR102313314B1 (ko) 2013-10-23 2014-10-22 신경퇴행성 질환 및 통증의 예방 및 치료에 사용하기 위한 화합물

Country Status (14)

Country Link
US (1) US10301348B2 (https=)
EP (1) EP3060566B1 (https=)
JP (1) JP6534997B2 (https=)
KR (1) KR102313314B1 (https=)
CN (1) CN106414456B (https=)
AU (1) AU2014340114B2 (https=)
BR (1) BR112016008901B1 (https=)
CA (1) CA2927699C (https=)
IL (1) IL245103B (https=)
MX (1) MX367707B (https=)
RU (1) RU2695358C2 (https=)
SG (1) SG11201603063WA (https=)
WO (1) WO2015061426A1 (https=)
ZA (1) ZA201603118B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201707513QA (en) * 2015-05-29 2017-10-30 Univ Leland Stanford Junior Nucleoside agents for the reduction of the deleterious activity of extended nucleotide repeat containing genes
US11753432B2 (en) 2017-01-27 2023-09-12 Academia Sinica Compound with analgesic effect for use in prevention and treatment of pain
CA3250090A1 (en) * 2022-02-10 2023-08-17 Academia Sinica METHOD FOR TREATMENT OF A SPINAL CORD INJURY AND CORRESPONDING COMPOSITION
TWI910441B (zh) * 2022-07-07 2026-01-01 中央研究院 治療思覺失調症之方法及用於其中之組成物
JP2026503973A (ja) * 2022-12-29 2026-02-03 中央研究院 睡眠障害を処置する方法及びそれに使用するための組成物
EP4680230A1 (en) * 2023-03-17 2026-01-21 Academia Sinica Method of treating tuberous sclerosis complex or epilepsy and composition for use therein

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003148A2 (en) 1986-10-31 1988-05-05 Warner-Lambert Company Heteroaromatic derivatives of adenoside
US20120295863A1 (en) 2009-11-13 2012-11-22 Yun-Lian Lin Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases
WO2013120076A1 (en) 2012-02-09 2013-08-15 Brand Bumps, LLC Decorative detectable warning panel having improved grip

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034381A (en) * 1988-01-07 1991-07-23 Ciba-Geigy Corporation 2-(substituted amino) adenosines as antihypertensives
AU654507B2 (en) * 1990-09-25 1994-11-10 Rhone-Poulenc Rorer International (Holdings) Inc. Compounds having antihypertensive and anti-ischemic properties
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
CN102812033B (zh) 2009-12-10 2015-11-25 中国医学科学院药物研究所 N6-取代腺苷衍生物和n6-取代腺嘌呤衍生物及其用途
CN104363757B (zh) 2012-02-11 2017-05-24 中央研究院 治疗疼痛的方法及组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003148A2 (en) 1986-10-31 1988-05-05 Warner-Lambert Company Heteroaromatic derivatives of adenoside
US20120295863A1 (en) 2009-11-13 2012-11-22 Yun-Lian Lin Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases
WO2013120076A1 (en) 2012-02-09 2013-08-15 Brand Bumps, LLC Decorative detectable warning panel having improved grip

Also Published As

Publication number Publication date
BR112016008901A2 (pt) 2020-05-12
AU2014340114B2 (en) 2018-10-18
EP3060566A1 (en) 2016-08-31
US10301348B2 (en) 2019-05-28
NZ719740A (en) 2021-02-26
MX2016005174A (es) 2016-08-11
RU2016118282A (ru) 2017-11-28
JP6534997B2 (ja) 2019-06-26
CA2927699C (en) 2022-07-05
EP3060566B1 (en) 2018-09-05
SG11201603063WA (en) 2016-05-30
RU2016118282A3 (https=) 2018-06-18
RU2695358C2 (ru) 2019-07-23
KR20160086852A (ko) 2016-07-20
EP3060566A4 (en) 2017-06-14
IL245103A0 (en) 2016-06-30
CN106414456B (zh) 2018-12-14
AU2014340114A1 (en) 2016-05-26
BR112016008901B1 (pt) 2022-08-23
US20160264613A1 (en) 2016-09-15
JP2016535019A (ja) 2016-11-10
ZA201603118B (en) 2019-04-24
CN106414456A (zh) 2017-02-15
WO2015061426A1 (en) 2015-04-30
IL245103B (en) 2019-02-28
CA2927699A1 (en) 2015-04-30
MX367707B (es) 2019-09-03

Similar Documents

Publication Publication Date Title
KR102313314B1 (ko) 신경퇴행성 질환 및 통증의 예방 및 치료에 사용하기 위한 화합물
EP3781564B1 (en) Pyridazine derivatives for the treatment of cancer
JP7248750B2 (ja) オピオイド受容体リガンド並びにそれらの使用方法及び製造方法
Zhang et al. MANF protects dopamine neurons and locomotion defects from a human α-synuclein induced Parkinson's disease model in C. elegans by regulating ER stress and autophagy pathways
CN103442714B (zh) 可用于胆固醇动员的化合物、组合物和方法
EP3810587A1 (en) Substituted alkoxypyridinyl indolsulfonamides
JP2024515194A (ja) １７β－ヒドロキシステロイドデヒドロゲナーゼの１３型を標的とするｓｉＲＮＡ及びｓｉＲＮＡ複合体
WO2023109940A1 (zh) 靶向lpa的sirna及缀合物
Hou et al. Adenosine receptor A1‐A2a heteromers regulate EAAT2 expression and glutamate uptake via YY1‐induced repression of PPARγ transcription
EP3937923B1 (en) Synthetic retinoids for use in rar activation
TWI644916B (zh) 哌喃并二吡啶化合物
Chen et al. Design, synthesis and neurite outgrowth activity of novel ganglioside GM1 derivatives by remodeling of the fatty acid moiety
TWI650328B (zh) 用於預防及治療神經退化疾病及疼痛之化合物
TWI668007B (zh) 用於預防及治療神經退化疾病及疼痛之化合物
EP3980541A1 (en) Aptamers against transferrin receptor (tfr)
WO2024064923A9 (en) Covalent, chemogenetic activators for k2p potassium channels and uses thereof
HK40059400B (en) Synthetic retinoids for use in rar activation
NZ719740B2 (en) Compounds for use in prevention and treatment of neurodegenerative diseases and pain
HK1196035A (en) Opioid receptor ligands and methods of using and making same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160523

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190827

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210209

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210818

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20211008

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20211012

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee